Author [ Title] Type Year
Filters: Author is Perales, Miguel-Angel [Clear All Filters]
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biol Blood Marrow Transplant. 2020..
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4(16):3977-3989.
CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020.
CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and anti-thymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse. Biol Blood Marrow Transplant. 2015.
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021.
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676-686.
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016.
Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biol Blood Marrow Transplant. 2015..
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020.
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019.
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.
Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the ASBMT. Biol Blood Marrow Transplant. 2015.
Immune reconstitution after cord blood transplantation: peculiarities, clinical implications and management strategies. Cytotherapy. 2015;17(6):711-722..
Impact of preemptive therapy for Cytomegalovirus on hospitalizations and cost after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020..
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. Transplant Cell Ther. 2021.